Here are the DEF 14A proxy statements from A SPAC III Acquisition Corp. Right (ASPCR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ASPCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASPCR filings page.
ASPAC III Acquisition Corp. (ASPC) asks shareholders to extend its deadline for completing a business combination from November 12, 2026, to November 12, 2028, subject to shareholder approval and registration of the amended charter. No additional funds would be deposited into the trust account. The proposed Bioserica transaction is not being voted on at this meeting.
As of September 22, 2026, the trust held approximately $3.06 million and the estimated redemption price was approximately $10.82 per public share. Nasdaq notified the company that its stockholders’ equity for the quarter ended March 31, 2026, was below the $2.5 million continued-listing requirement, with until November 12, 2026, to regain compliance. The sponsor indicated it will vote for the extension; its 1,785,000 shares represented approximately 76.4% of outstanding shares on the record date. Nasdaq rules separately require a business combination within 36 months of the IPO.